Open Access

Par Abdelhamid Benhmade En quatre semaines, la situation est devenue extrêmement alarmante sur le continent africain. « Les populations africaines vivent l’un des pires épisodes pandémiques...

Par Abdelhamid Benhmade Sans pour autant être d’un optimisme béat ni sombrer dans un pessimisme démesuré, il est clair que la dérogation aux droits de...

By Chidi Oguamanam and Sarah O’Flaherty The State of Affairs As the vaccination rate rises in Canada and other developed nations, developing countries globally continue to record an...

Par Abdelhamid Benhmade À quelques semaines près, l’Organisation mondiale du commerce tiendra sa douzième conférence ministérielle pour discuter de plusieurs dossiers tant complexes qu’épineux, entre...

By Victor Nzomo In the midst of two decades of TRIPS and three decades of openness, more than 400 delegates from over 50 countries converged...

Jeremy de Beer, Izabella Sowa et Kristen HolmanDate de publication: septembre 2017Télécharger: Chapitre 2: Cadres d’analyse de l’innovation africaine : l’entrepreneuriat, l’économie informelle et...

To assist trade policymakers in the development of a framework, this paper explores IP issues, perspectives, and priorities related to both the CFTA and PAIPO. It suggests that process and substance issues are each important to create fair and balanced IP systems on the continent that stimulate innovation, growth, and competition.

In the recently concluded ‘African Ministerial Conference: Intellectual Property for an Emerging Africa’ organized in part by WIPO (here), one cannot help but think that all roads leading to creativity and innovation are paved with intellectual property (IP) laws and institutions. Put differently, the level of creativity and innovation in a society is dependent solely on how we tinker with and enforce IP laws. This ‘IP parochialism’, as I call it, is manifest in the conference program. Of course, the response would be that the conference was solely about IP and as such there was no need to look beyond IP. This is an erroneous view.

Edited by: Chidi Oguamanam. When the oral history of a medicinal plant as a genetic resource is used to develop a blockbuster drug, how is the contribution of Indigenous Peoples recognized in research and commercialization? What other ethical, legal, and policy issues come into play? Is it accurate for countries to self-identify as users or providers of genetic resources?

By Michael Dao On March 28th, 2019, the University of Ottawa hosted the Shifting Horizons: Managing Your Research Data Conference, a day-long series of workshops for researchers. I...